EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieVergleichsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial

Natalie Dennis, Kyle Dunton, Christopher Livings, Nataliya Bogoeva, Siobhan Bourke, Yemi Oluboyede, Erika Hamilton, Hiroji Iwata, Javier Cortés

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2024.115192 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Natalie Dennis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Daiichi Sankyo Oncology France, Rueil-Malmaison, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Ado-Trastuzumab Emtansine, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daiichi-Sankyo, AstraZeneca, Daiichi Sankyo Europe GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAdo-Trastuzumab EmtansineErb-b2 Receptor Tyrosine KinasesTrastuzumabImmunoconjugatesAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleQuality of LifeMiddle AgedAgedAdultNeoplasm MetastasisCamptothecin

Stichwörter der Autor:innen

HER2-positive breast cancerMetastatic breast cancerQ-TWiSTQuality-adjusted survivalTrastuzumab deruxtecan (T-DXd)

Substanzen

Ado-Trastuzumab EmtansineErb-b2 Receptor Tyrosine KinasesTrastuzumabImmunoconjugatesAntineoplastic Agents, ImmunologicalCamptothecinERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Daiichi Sankyo Oncology France, Rueil-Malmaison, France.
  • Daiichi Sankyo, London, United Kingdom.
  • AstraZeneca, London, United Kingdom.
  • Putnam, Ceva House, Excelsior Road, Ashby-De-La-Zouch LE65 1NG, United Kingdom. Electronic address: nataliya.bogoeva@putassoc.com.
  • Putnam, Ceva House, Excelsior Road, Ashby-De-La-Zouch LE65 1NG, United Kingdom.
  • Sarah Cannon Research Institute, Nashville, United States.

Förderung

  • Daiichi-Sankyo
  • AstraZeneca
  • Daiichi Sankyo Europe GmbH

Zitieren

APA

Dennis, N., Dunton, K., Livings, C., Bogoeva, N., Bourke, S., Oluboyede, Y., Hamilton, E., Iwata, H., & Cortés, J. (2025). Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115192

Vancouver

Dennis N, Dunton K, Livings C, Bogoeva N, Bourke S, Oluboyede Y, et al. Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2024.115192

BibTeX
@article{Dennis2025,
  author = {Dennis, Natalie and Dunton, Kyle and Livings, Christopher and Bogoeva, Nataliya and Bourke, Siobhan and Oluboyede, Yemi and Hamilton, Erika and Iwata, Hiroji and Cortés, Javier},
  title = {Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2024.115192}
}
Kostenlos starten →